Inventiva (IVA.PA) Stock Price

Inventiva Price

Euronext·CLOSED
3.68EUR-0.23 (-6.19 %)
Market closed

Over the last 12 years Inventiva grew revenue by 3.2% annually, reaching 4.48 M EUR. For Inventiva, the net margin of -7,899.6% is down versus -1,183.5% a few years ago. The consensus 12-month price target for Inventiva is 11.63 EUR, about 216.0% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus. The stock trades about 34% above its 52-week low.

Inventiva stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Inventiva over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Inventiva stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Inventiva's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Inventiva Stock Price History
DateInventiva Price
7/24/20263.68 EUR
7/21/20263.91 EUR
7/20/20263.86 EUR
7/17/20263.92 EUR
7/16/20263.83 EUR
7/15/20263.87 EUR
7/14/20263.82 EUR
7/13/20263.71 EUR
7/10/20263.73 EUR
7/9/20263.73 EUR
7/8/20263.56 EUR
7/7/20263.33 EUR
7/6/20263.41 EUR
7/3/20263.38 EUR
7/2/20263.28 EUR
7/1/20263.17 EUR
6/30/20263.22 EUR
6/29/20263.03 EUR
6/26/20263.07 EUR
6/25/20262.97 EUR
6/24/20263.11 EUR
6/23/20263.17 EUR
6/22/20263.01 EUR
6/19/20263.00 EUR
6/18/20263.10 EUR
6/17/20263.07 EUR
6/16/20263.18 EUR
6/15/20263.37 EUR
6/12/20263.31 EUR
6/11/20263.24 EUR
6/10/20263.14 EUR
6/9/20263.26 EUR
6/8/20263.50 EUR
6/5/20263.56 EUR
6/4/20263.36 EUR
6/3/20263.28 EUR
6/2/20263.43 EUR
6/1/20264.20 EUR
5/29/20264.51 EUR
5/28/20264.57 EUR
5/27/20264.65 EUR
5/26/20264.64 EUR
5/25/20264.68 EUR
5/22/20264.49 EUR
5/21/20264.39 EUR
5/20/20264.30 EUR
5/19/20264.25 EUR
5/18/20264.40 EUR
5/15/20264.81 EUR
5/14/20264.83 EUR
5/13/20264.78 EUR
5/12/20264.91 EUR
5/11/20265.02 EUR
5/8/20264.55 EUR
5/7/20264.51 EUR
5/6/20264.55 EUR
5/5/20264.69 EUR
5/4/20264.34 EUR
4/30/20264.31 EUR
4/29/20264.20 EUR
4/28/20264.31 EUR
4/27/20264.34 EUR
4/24/20264.37 EUR
4/23/20264.50 EUR
4/22/20264.56 EUR
4/21/20264.59 EUR
4/20/20264.78 EUR
4/17/20264.82 EUR
4/16/20264.74 EUR
4/15/20264.63 EUR
4/14/20264.36 EUR
4/13/20264.41 EUR
4/10/20264.53 EUR
4/9/20264.39 EUR
4/8/20264.55 EUR
4/7/20264.55 EUR
4/2/20264.72 EUR
4/1/20264.57 EUR
3/31/20264.75 EUR
3/30/20264.80 EUR
3/27/20265.00 EUR
3/26/20265.15 EUR
3/25/20265.19 EUR
3/24/20265.20 EUR
3/23/20265.24 EUR
3/20/20265.11 EUR
3/19/20265.20 EUR
3/18/20265.13 EUR
3/17/20265.28 EUR
3/16/20265.19 EUR
3/13/20265.17 EUR
3/12/20265.32 EUR
3/11/20265.56 EUR
3/10/20265.68 EUR
3/9/20265.31 EUR
3/6/20265.19 EUR
3/5/20265.31 EUR
3/4/20265.14 EUR
3/3/20265.09 EUR
3/2/20265.31 EUR
2/27/20265.49 EUR
2/26/20265.55 EUR
2/25/20265.79 EUR
2/24/20265.72 EUR
2/23/20265.65 EUR
2/20/20265.62 EUR
2/19/20265.59 EUR
2/18/20265.37 EUR
2/17/20265.24 EUR
2/16/20265.28 EUR
2/13/20265.29 EUR
2/12/20265.25 EUR
2/11/20265.13 EUR
2/10/20265.35 EUR
2/9/20265.17 EUR
2/6/20265.02 EUR
2/5/20265.10 EUR
2/4/20265.07 EUR
2/3/20265.28 EUR
2/2/20265.14 EUR
1/30/20265.00 EUR
1/29/20265.23 EUR
1/28/20265.70 EUR
1/27/20265.74 EUR
1/26/20265.83 EUR
1/23/20265.98 EUR
1/22/20265.71 EUR
1/21/20265.52 EUR
1/20/20265.15 EUR
1/19/20265.31 EUR
1/16/20265.71 EUR
1/15/20265.28 EUR
1/14/20265.06 EUR
1/13/20264.90 EUR
1/12/20264.41 EUR
1/9/20264.09 EUR
1/8/20264.07 EUR
1/7/20264.24 EUR
1/6/20263.92 EUR
1/5/20263.94 EUR
1/2/20264.05 EUR
12/31/20253.94 EUR
12/30/20253.90 EUR
12/29/20253.91 EUR
12/24/20253.76 EUR
12/23/20253.78 EUR
12/22/20253.78 EUR
12/19/20253.65 EUR
12/18/20253.68 EUR
12/17/20253.86 EUR
12/16/20253.76 EUR
12/15/20253.72 EUR
12/12/20253.76 EUR
12/11/20253.80 EUR
12/10/20253.81 EUR
12/9/20253.64 EUR
12/8/20253.50 EUR
12/5/20253.45 EUR
12/4/20253.53 EUR
12/3/20253.48 EUR
12/2/20253.66 EUR
12/1/20253.68 EUR
11/28/20253.66 EUR
11/27/20253.75 EUR
11/26/20253.71 EUR
11/25/20253.76 EUR
11/24/20253.50 EUR
11/21/20253.46 EUR
11/20/20253.61 EUR
11/19/20253.46 EUR
11/18/20253.44 EUR
11/17/20253.53 EUR
11/14/20253.39 EUR
11/13/20253.27 EUR
11/12/20253.35 EUR
11/11/20253.26 EUR
11/10/20253.30 EUR
11/7/20253.55 EUR
11/6/20253.71 EUR
11/5/20253.60 EUR
11/4/20253.67 EUR
11/3/20253.52 EUR
10/31/20253.60 EUR
10/30/20253.41 EUR
10/29/20253.77 EUR
10/28/20253.34 EUR
10/27/20253.10 EUR
10/24/20253.04 EUR
10/23/20253.11 EUR
10/22/20253.13 EUR
10/21/20253.27 EUR
10/20/20253.33 EUR
10/17/20253.43 EUR
10/16/20253.57 EUR
10/15/20253.64 EUR
10/14/20254.00 EUR
10/13/20253.78 EUR
10/10/20253.98 EUR
10/9/20254.20 EUR
10/8/20254.51 EUR
10/7/20254.76 EUR
10/6/20255.05 EUR
10/3/20255.34 EUR
10/2/20255.20 EUR
10/1/20254.97 EUR
9/30/20254.85 EUR
9/29/20254.94 EUR
9/26/20255.05 EUR
9/25/20255.11 EUR
9/24/20254.68 EUR
9/23/20254.74 EUR
9/22/20254.67 EUR
9/19/20254.58 EUR
9/18/20254.49 EUR
9/17/20254.39 EUR
9/16/20254.41 EUR
9/15/20254.52 EUR
9/12/20254.63 EUR
9/11/20254.73 EUR
9/10/20254.71 EUR
9/9/20254.53 EUR
9/8/20254.49 EUR
9/5/20254.47 EUR
9/4/20254.47 EUR
9/3/20254.80 EUR
9/2/20254.50 EUR
9/1/20254.55 EUR
8/29/20254.89 EUR
8/28/20254.78 EUR
8/27/20254.63 EUR
8/26/20254.07 EUR
8/25/20254.03 EUR
8/22/20253.88 EUR
8/21/20253.89 EUR
8/20/20253.89 EUR
8/19/20253.80 EUR
8/18/20253.65 EUR
8/15/20253.40 EUR
8/14/20253.51 EUR
8/13/20253.20 EUR
8/12/20253.00 EUR
8/11/20252.93 EUR
8/8/20252.90 EUR
8/7/20252.87 EUR
8/6/20252.86 EUR
8/5/20252.82 EUR
8/4/20252.79 EUR
8/1/20252.79 EUR
7/31/20252.85 EUR
7/30/20252.83 EUR
7/29/20252.90 EUR
7/28/20252.75 EUR
7/25/20252.76 EUR
Access this data via the Eulerpool API
Get Free API Key

Inventiva Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
372,000.00 EUR
-29.72 M EUR
-31.62 M EUR
Jan 1, 2021
4.19 M EUR
-52.11 M EUR
-49.64 M EUR
Jan 1, 2022
12.18 M EUR
-57.11 M EUR
-54.27 M EUR
Jan 1, 2023
17.48 M EUR
-105.59 M EUR
-110.43 M EUR
Jan 1, 2024
14.72 M EUR
-97.56 M EUR
-184.21 M EUR
Jan 1, 2025
4.48 M EUR
-136.33 M EUR
-354.14 M EUR
Jan 1, 2026 (e)
6.73 M EUR
-120.42 M EUR
-42.68 M EUR
Jan 1, 2027 (e)
108.56 M EUR
-129.29 M EUR
-47.55 M EUR

Inventiva Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 25, 2026, 2:14 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e
3.003.004.009.006.003.006.00–4.0012.0017.0014.004.006.00108.00
––33.33125.00-33.33-50.00100.00––200.0041.67-17.65-71.4350.001,700.00
33.3333.3375.0077.7883.3366.67100.00–75.00100.00100.0064.2925.0025.0025.00
1.001.003.007.005.002.006.001.003.0012.0017.009.001.001.5027.00
-12.00-13.00-15.00-13.00-20.00-33.00-30.00-29.00-52.00-57.00-105.00-97.00-136.00-120.00-129.00
-400.00-433.33-375.00-144.44-333.33-1,100.00-500.00–-1,300.00-475.00-617.65-692.86-3,400.00-2,000.00-119.44
-7.00-7.00-8.00-7.00-17.00-33.00-30.00-31.00-49.00-54.00-110.00-184.00-354.00-42.00-47.00
––14.29-12.50142.8694.12-9.093.3358.0610.20103.7067.2792.39-88.1411.90
10.0310.0310.0310.0316.3922.2226.7838.3239.6142.0448.6667.58637.08637.08637.08
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Inventiva generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Inventiva retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Inventiva's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Inventiva has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Inventiva's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Inventiva stock margins

The Inventiva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Inventiva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Inventiva.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
100.00 %
-7,988.71 %
-8,500.81 %
Jan 1, 2021
75.75 %
-1,242.58 %
-1,183.50 %
Jan 1, 2022
100.00 %
-468.92 %
-445.64 %
Jan 1, 2023
100.13 %
-604.14 %
-631.84 %
Jan 1, 2024
62.47 %
-662.58 %
-1,251.10 %
Jan 1, 2025
35.07 %
-3,040.98 %
-7,899.58 %
Jan 1, 2026 (e)
35.07 %
-1,788.63 %
-633.98 %
Jan 1, 2027 (e)
35.07 %
-119.10 %
-43.80 %

Inventiva Stock Revenue, EBIT, Earnings per Share

The Inventiva earnings per share therefore indicates how much revenue Inventiva has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.01 EUR
-0.78 EUR
-0.83 EUR
Jan 1, 2021
0.11 EUR
-1.32 EUR
-1.25 EUR
Jan 1, 2022
0.29 EUR
-1.36 EUR
-1.29 EUR
Jan 1, 2023
0.36 EUR
-2.17 EUR
-2.27 EUR
Jan 1, 2024
0.22 EUR
-1.44 EUR
-2.73 EUR
Jan 1, 2025
0.01 EUR
-0.21 EUR
-0.56 EUR
Jan 1, 2026 (e)
0.11 EUR
-0.19 EUR
-0.71 EUR
Jan 1, 2027 (e)
1.82 EUR
-0.20 EUR
-0.80 EUR

Inventiva business model & stock analysis

Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie.

Inventiva SWOT Analysis

Strengths

Inventiva SA possesses several key strengths that contribute to its competitiveness in the market:

  • Strong and experienced management team with a successful track record.
  • Robust portfolio of intellectual property rights and patents.
  • Solid financial position and stable revenue streams.
  • Strategic partnerships with leading industry players.
  • Excellent R&D capabilities and innovative product pipeline.

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Weaknesses

Despite its strengths, Inventiva SA also faces certain weaknesses that may hamper its performance:

  • Limited market presence and brand recognition compared to larger competitors.
  • Reliance on a relatively small customer base, which increases vulnerability to economic fluctuations.
  • Overdependence on a specific technology or product line.

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Opportunities

Inventiva SA can leverage the following opportunities to further grow and expand its business:

  • Emerging markets offer untapped potential for market penetration and increased sales.
  • Growing demand for innovative solutions in the target industry.
  • Strategic alliances and collaborations to access new markets and expand product offerings.
  • Advancements in technology that align with Inventiva SA's expertise and capabilities.

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Threats

Inventiva SA faces several external threats that impede its growth and profitability:

  • Intense competition from established players with greater resources and market presence.
  • Economic downturns or fluctuations affecting consumer purchasing power.
  • Regulatory and legal challenges in intellectual property protection.
  • Disruptive technologies that may render current products or services obsolete.

Inventiva Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Inventiva historical P/E ratio, EBIT multiple, and P/S ratio

Inventiva annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Inventiva shares outstanding

The number of shares of Inventiva was 637.08 M in 2025. This indicates how many shares Inventiva is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
38.32 M Stocks
Jan 1, 2021
39.61 M Stocks
Jan 1, 2022
42.04 M Stocks
Jan 1, 2023
48.66 M Stocks
Jan 1, 2024
67.58 M Stocks
Jan 1, 2025
637.08 M Stocks
Jan 1, 2026 (e)
637.08 M Stocks
Jan 1, 2027 (e)
637.08 M Stocks

Current Inventiva forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy93.33 % (14)
Hold6.67 % (1)
Sell0.00 % (0)
12M Price Target
11.63
Last Price
3.81
Currency
EUR
12M Return Potential
205.60 %
LTM Return
0 %

Inventiva Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
3/27/2024-0.79EUR0.00EUR2023 Q4

Inventiva shareholder structure

% Name
24.78276%
The Invus Group, LLC
The Invus Group, LLC
16.92663%
Eventide Asset Management, LLC
Eventide Asset Management, LLC
14.43348%
Samsara BioCapital, LLC
Samsara BioCapital, LLC
13.96941%
New Enterprise Associates (NEA)
New Enterprise Associates (NEA)
13.14759%
BVF Partners L.P.
BVF Partners L.P.
12.39138%
Great Point Partners, LLC
Great Point Partners, LLC

Inventiva Executives and Management Board

AS

Dr. Annick Schwebig

(73)

Independent Director

Compensation61,200.00 EUR
HM

Mr. Heinz Maeusli

(62)

Independent Director

Compensation49,200.00 EUR
MZ

Ms. Martine Zimmerman

(55)

Independent Director

Compensation21,600.00 EUR
MP

Dr. Mark Pruzanski

(57)

Chairman of the Board

AO

Mr. Andrew Obenshain

(50)

Chief Executive Officer, Director · since 2025

Inventiva Supply Chain

Inventiva Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#Name1M3M6M1Y2YTrend
1
AbbVie
Supplier
0.41
-0.29
-0.85
-0.72
-0.27

Frequently asked questions about Inventiva

The business model of Inventiva SA focuses on the development and commercialization of innovative therapies for the treatment of various diseases. As a biopharmaceutical company, Inventiva SA aims to discover and develop small molecule drugs that target various nuclear receptors involved in the regulation of gene expression. By leveraging its expertise in nuclear receptors, Inventiva SA aims to bring novel therapies to market that can address unmet medical needs. With a strong pipeline of drug candidates in various stages of development, Inventiva SA is dedicated to improving patients' lives and creating value for its shareholders through the research and development of innovative therapies.

All fundamentals and in-depth analysis of Inventiva

Our stock analysis for Inventiva stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inventiva. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Inventiva Stock
Inventiva Revenue→
Inventiva Stock
Inventiva Net Income→
Inventiva Stock
Inventiva P/E→
Inventiva Stock
Inventiva P/S→
Inventiva Stock
Inventiva EBIT→
Inventiva Stock
Inventiva Dividend→
Inventiva Stock
Inventiva Directors Dealings→
Inventiva Stock
Inventiva Stocks→
Inventiva Stock
Inventiva Market capitalization→
Inventiva Stock
Inventiva Debt→
Inventiva Stock
Inventiva Liabilities→
Inventiva Stock
Inventiva Equity→
Inventiva Stock
Inventiva AAQS→
Inventiva Stock
Inventiva Employees→
Inventiva Stock
Inventiva ROE→
Inventiva Stock
Inventiva ROA→
Inventiva Stock
Inventiva ROCE→
Inventiva Stock
Inventiva News→
Inventiva Stock
Inventiva Analyst Price Targets→

Health Stocks

Inventiva SaInventisBio CoInventurus Knowledge SolutionsInventionmedInvex TherapeuticsInventage LabInvionInvent Medic SwedenInvivydInvech HoldingsINVO FertilityIntuitive SurgicalAll Stocks A–Z →